中文名:17ALPHA-DIHYDROEQUILIN,英文名:1,3,5(10), 7-ESTRATETRAEN-3,17-ALPHA-DIOL,CAS:,化学式:C18H22O2,分子量:270.37,MSDS.
Prepn. of 17alpha-dihydro-equilenin (I) and 17alpha-dihydroequilin (II) from equilin (III):- Oestrogenic agents. where R = benzyl or 2-tetrahydropyranyl. R' = C6H5, p-tolyl, p-bromophenyl, p-chlorophenyl or 2-naphthyl; T = tetrahydropyranyl. Group R when benzyl was removed by...
17ALPHA-DIHYDROEQUILIN (50 MG) CAS:6639-99-2 英文名:17ALPHA-DIHYDROEQUILIN (50 MG) 更多产品信息 签到 购物指南 用户注册 购物指南 销售条款 会员介绍 额度说明 支付方式 预存款 支付宝/微信 汇款或转账 发票说明 配送说明 配送说明 运费说明 验货签收 帮助中心 售后政策 退换货说明 退款说明 产品...
Yellow Solid 17alpha-Dihydroequilenin is a 3-hydroxy steroid.Product Supplier 2Products SynZeal Research Pvt Ltd 17ALPHA-DIHYDROEQUILIN (50 MG) Updatetime:Jan 01 2022 Description: Molecular Formula: C18H20O2 Send Inquiry Pharmaffiliates Analytics and Synthetics P. Ltd 17α-Dihydro Equilenin ...
Verfahren zur herstellung von 17 alpha-dihydroequilenin und 17 alpha-dihydroequilin Process for the preparation of 17 alpha-dihydroequilenin, 17 alpha-dihydroequilinVerfahren zur herstellung von 17 alpha-dihydroequilenin und 17 alpha-dihydroequilin Process for the preparation of 17 alpha-dihydroequi...
17 alpha-dihydroequilin *** Synonym EPY0000053 References 10mg 下一个:EPY0000054上一个:EPY0000052 联系我们 电话:021-60498804 邮箱:info@e-biochem.com 地址:上海市徐汇区漕溪路258弄27号航星商务楼2-404 在线咨询联系方式二维码 服务热线 021-60498804 ...
英文名称:17 alpha-dihydroequilin (Y0000053) 英文同义词:17 alpha-dihydroequilin (Y0000053) CAS号: 分子式: 分子量:0 EINECS号: Mol文件:Mol File 17 alpha-dihydroequilin (Y0000053) 信息错误报告 提交 按省份浏览17 alpha-dihydroequilin (Y0000053)供应商 ...
The present invention is also directed to a method of treating a menopausal condition in a female in need thereof, said method comprising vaginally administering a pharmaceutical vaginal cream composition comprising a conjugated estrogen twice per week for at least 2 weeks.Salah Ahmed...
17 .alpha.-Dihydroequilin hapten and assay methodPemmaraju N Rao
4379780 17 Alpha-dihydroequilin hapten and assay method: Pemmaraju N Rao assigned to American Home Products Corporationdoi:10.1016/0047-0740(85)90044-0ELSEVIERInternational Journal of Nuclear Medicine & Biology